Company Description
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company.
It offers CellFX System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; CellFX nsPFA Percutaneous Electrode system for soft tissue ablation in surgical setting; CellFX nsPFA Cardiac Clamp designed for use in surgical treatment of atrial fibrillation (AF); CellFX nsPFA 360° Cardiac Catheter designed to provide a circumferential, or circular, ablation in a single treatment cycle; and The CellFX Consol, a tunable, software-enabled, and console-based platform designed to accommodate the clinical workflow preferred by physicians.
The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015.
Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
| Country | United States |
| Founded | 2014 |
| IPO Date | May 18, 2016 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 75 |
| CEO | Paul LaViolette |
Contact Details
Address: 601 Brickell Key Drive, Suite 1080 Miami, Florida 33131 United States | |
| Phone | 510 906 4600 |
| Website | pulsebiosciences.com |
Stock Details
| Ticker Symbol | PLSE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001625101 |
| CUSIP Number | 74587B101 |
| ISIN Number | US74587B1017 |
| Employer ID | 46-5696597 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Paul Arthur LaViolette | President, Chief Executive Officer and Co-Chairman of the Board |
| Darrin R. Uecker | Chief Technology Officer and Director |
| Kevin P. Danahy | Chief Commercial Officer |
| Jon Skinner | Chief Financial Officer |
| Edison Manuel | Vice President of Operations |
| Steven T. Weber | Vice President of Accounting, Principal Accounting Officer and Global Corporate Controller |
| Kenneth B. Stratton Esq., J.D. | General Counsel and Corporate Secretary |
| Patty Perla | Vice President of Human Resources |
| Mitchell E. Levinson | Chief Strategy Officer |
| David Danitz | Senior Vice President of Engineering |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 13, 2025 | 8-K | Current Report |
| Nov 5, 2025 | 10-Q | Quarterly Report |
| Nov 5, 2025 | 8-K | Current Report |
| Oct 28, 2025 | DEF 14A | Other definitive proxy statements |
| Oct 28, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Oct 24, 2025 | 8-K | Current Report |
| Oct 10, 2025 | 8-K | Current Report |
| Oct 1, 2025 | 8-K | Current Report |
| Sep 18, 2025 | 144 | Filing |
| Sep 11, 2025 | 144 | Filing |